Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Rises By 277.7%

SciSparc Ltd. (NASDAQ:SPRC) saw a significant increase in short interest in July. As of July 31st, there was short interest totaling 37,966 shares, an increase of 277.7% from the July 15th total of 10,052 shares. Based on an average daily volume of 747,372 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.8% of the shares of the company are sold short.

SciSparc Stock Performance

NASDAQ:SPRC opened at $6.60 on Thursday. The company has a 50-day moving average of $6.61 and a 200-day moving average of $5.86. SciSparc has a twelve month low of $2.98 and a twelve month high of $80.10.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen raised shares of SciSparc to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, SciSparc presently has an average rating of “Sell”.

SciSparc Company Profile

SciSparc AG is a clinical?stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low?intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.